Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #75 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 4 strong
The short version
The company expects to achieve double-digit growth in the coming quarters despite some sales reversals affecting recent results. The company expects to achieve double-digit revenue growth for the full year, aiming for around 12%+ growth in the remaining quarters. - Growth trajectory is expected to improve in upcoming quarters after a relatively slower Q1. - EBITDA margins are anticipated to normalize to around 30-32% as operational efficiencies improve and energy costs stabilize. - R&D investment will increase to support sustained growth and margin improvement, though immediate margin expansion is not expected. - The U.S.
From Advanced Enzyme Technologies Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- The company expects to achieve double-digit growth in the coming quarters despite some sales reversals affecting recent results.
- Growth in the U.S. market is projected at around 8-10%, driven by branding efforts and gradual strategic changes rather than immediate product launches.
- The business model focuses on sustained growth with a steady customer base, with 70-80% customers being consistent and 20-30% changing.
- Growth is expected to come from a combination of new and existing products across various segments.
- Biocatalysis is considered a high-growth segment, with good growth anticipated particularly in the second half of the year.
2 more points from Advanced Enzyme Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans a total CapEx of INR 123 crore as discussed in the AGM.
- Approximately INR 20 crore is for normal capital expenditure, INR 50 crore will be for R&D (work in progress), and the remaining is for growth.
- The CapEx is expected to span FY27, with about INR 20 crore possibly extending into Q2 FY27.
- Current fermentation capacity utilization is around 70-75%, prompting potential capacity expansion.
- Plans to increase capacity will be taken up in the next quarter.
2 more points from Advanced Enzyme Technologies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Mukund Kabra mentions variability of 20-30% in customers quarter-on-quarter, indicating some order fluctuation.
- There’s mention of some inventory and order-related delays or complexities at the customer level.
- Mukund Kabra signals optimism about a "robust pipeline of sales orders" going forward.
2 more points from Advanced Enzyme Technologies Ltd's call on order book
Create a free account to keep reading this call
Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹203 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Advanced Enzyme Technologies Ltd's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharmaceuticals Ltd (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Advanced Enzyme Technologies Ltd Q1 FY27 results?
The company expects to achieve double-digit growth in the coming quarters despite some sales reversals affecting recent results. The company expects to achieve double-digit revenue growth for the full year, aiming for around 12%+ growth in the remaining quarters. - Growth trajectory is expected to improve in upcoming quarters after a relatively slower Q1. - EBITDA margins are anticipated to normalize to around 30-32% as operational efficiencies improve and energy costs stabilize. - R&D investment will increase to support sustained growth and margin improvement, though immediate margin expansion is not expected. - The U.S.
What is Advanced Enzyme Technologies Ltd share price analysis?
Advanced Enzyme Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 19.0 with a market cap of ₹2,989 Cr. Investors should review the full earnings analysis for detailed insights.
Is Advanced Enzyme Technologies Ltd planning capital expenditure?
The company plans a total CapEx of INR 123 crore as discussed in the AGM.
Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.